PharmAust Limited (ASX: $PAA) has requested a trading halt for its securities pending the announcement of Phase 1 MND Study Top-Line Results. The company aims to keep the securities in pre-open until the earlier of the announcement or the commencement of trade on 28 February 2024. PharmAust Limited is not aware of any reason why the trading halt should not be granted or any other information necessary to inform the market about the trading halt.
The Company makes the request pending an announcement of Phase 1 MND Study Top-Line Results. The Company aims to keep the securities in pre-open until the earlier of an announcement or the commencement of trade on 28 February 2024. PharmAust Limited is not aware of any reason why the trading halt should not be granted or any other information necessary to inform the market about the trading halt.
PharmAust Limited (ASX: $PAA) has requested a trading halt for its securities pending the announcement of Phase 1 MND Study Top-Line Results. The company aims to keep the securities in pre-open until the earlier of the announcement or the commencement of trade on 28 February 2024. PharmAust Limited is not aware of any reason why the trading halt should not be granted or any other information necessary to inform the market about the trading halt. The announcement of the Phase 1 MND Study Top-Line Results is anticipated to be a significant development for the company, and investors are advised to stay updated with the company's future announcements for further insights into this key study.